Topotecan



Topotecan
Systematic (IUPAC) name
(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-
dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]
quinoline-3,14(4H,12H)-dione monohydrochloride
Identifiers
CAS number 119413-54-6
ATC code L01XX17
PubChem 6419854
DrugBank APRD00687
Chemical data
O5 •HCl 
mol
Pharmacokinetic data
Bioavailability NA
Protein binding 35%
Metabolism Hepatic
Half life 2-3 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

D (Au, U.S.)

Legal status

℞-only (U.S.), POM (UK)

Routes Intravenous infusion, oral

Topotecan hydrochloride (Hycamtin) is a chemotherapy agent that is a inhibitor. It is used to treat ovarian cancer and lung cancer, as well as other cancer types.

After GlaxoSmithKline received final FDA approval for Hycamtin Capsules on October 15, 2007, Topotecan is the first topoisomerase inhibitor for oral use.

Administration

IV, oral.

Side effects

  • Diarrhea
  • Low blood counts
  • Susceptibility to infection

See also

NCI Drug Dictionary Definition of Topotecan
NCI Drug Information for Patients

v • d • e
Mitotane
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Topotecan". A list of authors is available in Wikipedia.